GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) announce that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST.
Read the full article: GSK Enters Agreement to Acquire IDRx, Inc. //
Source: https://www.businesswire.com/news/home/20250112698434/en/GSK-Enters-Agreement-to-Acquire-IDRx-Inc.